Patents by Inventor Mark X. Sliwkowski

Mark X. Sliwkowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8163287
    Abstract: The invention relates to tumors expressing HER2 and EGFR, using HER2-dimerization inhibitors (HDIs) and EGFR inhibitors.
    Type: Grant
    Filed: July 19, 2006
    Date of Patent: April 24, 2012
    Assignee: Genentech, Inc.
    Inventors: Mark X. Sliwkowski, Stephen M. Kelsey
  • Patent number: 8142784
    Abstract: The present invention relates to antibody-drug conjugate compounds of Formula I: Ab-(L-D)p??I where one or more maytansinoid drug moieties (D) are covalently linked by L to an antibody (Ab) which binds to an ErbB receptor, or which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be used in methods of diagnosis or treatment of cancer, and other diseases and disorders.
    Type: Grant
    Filed: December 2, 2008
    Date of Patent: March 27, 2012
    Assignee: Genentech, Inc.
    Inventors: Allen J. Ebens, Jr., Frederic S. Jacobson, Paul Polakis, Ralph H. Schwall, Mark X. Sliwkowski, Susan D. Spencer
  • Publication number: 20120034247
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: July 22, 2011
    Publication date: February 9, 2012
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • Publication number: 20120034246
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: April 19, 2011
    Publication date: February 9, 2012
    Applicant: SEATTLE GENETICS, INC.
    Inventors: SVETLANA O. DORONINA, PETER D. SENTER, BRIAN E. TOKI, ALLEN J. EBENS, TONI BETH KLINE, PAUL POLAKIS, MARK X. SLIWKOWSKI, SUSAN D. SPENCER
  • Publication number: 20120027784
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: July 22, 2011
    Publication date: February 2, 2012
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • Publication number: 20120027783
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: July 22, 2011
    Publication date: February 2, 2012
    Applicant: Seattle Genetics, Inc.
    Inventors: SVETLANA O. DORONINA, PETER D. SENTER, BRIAN E. TOKI, ALLEN J. EBENS, TONI BETH KLINE, PAUL POLAKIS, MARK X. SLIWKOWSKI, SUSAN D. SPENCER
  • Publication number: 20120003248
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: April 29, 2011
    Publication date: January 5, 2012
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • Patent number: 7994135
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: August 9, 2011
    Assignee: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • Patent number: 7964567
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: June 21, 2011
    Assignee: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • Patent number: 7964566
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: June 21, 2011
    Assignee: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • Publication number: 20110117096
    Abstract: Tumors are identified as responsive to treatment with anti-HER2 antibodies by detecting the presence of a HER2/HER3 and/or HER2/HER1 protein complex or for HER2 phosphorylation in a sample of tumor cells. Patients suffering from a tumor comprising HER/2/HER1 and/or HER2/HER3 heterodimers and/or HER2 phosphorylation are treated with anti-HER2 antibodies, such as rhuMAb 2C4.
    Type: Application
    Filed: November 29, 2010
    Publication date: May 19, 2011
    Inventors: BIRGIT BOSSENMAIER, HANS-JOACHIM MÜLLER, HANS KOLL, MARK X. SLIWKOWSKI, STEPHEN MICHAEL KELSEY
  • Patent number: 7919254
    Abstract: This invention relates to methods of analyzing a tissue sample from a subject. In particular, the invention combines morphological staining and/or immunohistochemistry (IHC) with fluorescence in situ hybridization (FISH) within the same section of a tissue sample. The analysis can be automated or manual. The invention also relates to kits for use in the above methods.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: April 5, 2011
    Assignee: Genentech, Inc.
    Inventors: Robert L. Cohen, Mary Beth Gardiner, Mark X. Sliwkowski, Gregory T. Stelzer
  • Publication number: 20100255010
    Abstract: The invention provides anti-HER antibodies, including multispecific anti-HER antibodies, compositions comprising and methods of using these antibodies. Also provided herein are EGFR/HER3 multispecific antibodies that are less toxic than traditional EGFR antagonists.
    Type: Application
    Filed: March 19, 2010
    Publication date: October 7, 2010
    Applicant: Genentech, Inc.
    Inventors: Germaine Fuh, Lauric Haber, Gabriele Schaefer, Mark X. Sliwkowski
  • Publication number: 20100190964
    Abstract: The present invention concerns methods and means for controlling excessive proliferation and/or migration of smooth muscle cells, and in particular for treating stenosis, by using antagonists of a native ErbB4 receptor. The invention further concerns a method for the identification of ErbB4 agonists and antagonists capable of inhibiting or enhancing the proliferation or migration of smooth muscle cells.
    Type: Application
    Filed: April 2, 2010
    Publication date: July 29, 2010
    Inventors: Mary E. Gerritsen, Mark X. Sliwkowski
  • Patent number: 7745394
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: June 29, 2010
    Assignee: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • Publication number: 20100120053
    Abstract: This invention relates to methods of analyzing a tissue sample from a subject. In particular, the invention combines morphological staining and/or immunohistochemistry (IHC) with fluorescence in situ hybridization (FISH) within the same section of a tissue sample. The analysis can be automated or manual. The invention also relates to kits for use in the above methods.
    Type: Application
    Filed: January 15, 2010
    Publication date: May 13, 2010
    Inventors: ROBERT L. COHEN, Mary Beth Gardiner, Mark X. Sliwkowski, Gregory T. Stelzer
  • Patent number: 7704498
    Abstract: The present invention concerns methods and means for controlling excessive proliferation and/or migration of smooth muscle cells, and in particular for treating stenosis, by using antagonists of a native ErbB4 receptor. The invention further concerns a method for the identification of ErbB4 agonists and antagonists capable of inhibiting or enhancing the proliferation or migration of smooth muscle cells.
    Type: Grant
    Filed: June 24, 2008
    Date of Patent: April 27, 2010
    Assignee: Genentech, Inc.
    Inventors: Mary E. Gerritsen, Mark X. Sliwkowski
  • Patent number: 7674589
    Abstract: This invention relates to methods of analyzing a tissue sample from a subject. In particular the invention combines morphological staining and/or immunohistochemistry (IHC) with fluorescence in situ hybridization (FISH) within the same section of a tissue sample. The analysis can be automated or manual. The invention also relates to kits for use in the above methods.
    Type: Grant
    Filed: December 9, 2008
    Date of Patent: March 9, 2010
    Assignee: Genentech, Inc.
    Inventors: Robert L. Cohen, Mary Beth Gardiner, Mark X. Sliwkowski, Gregory T. Stelzer
  • Publication number: 20090202536
    Abstract: The present invention relates to antibody-drug conjugate compounds of Formula I: Ab-(L-D)p??I where one or more maytansinoid drug moieties (D) are covalently linked by L to an antibody (Ab) which binds to an ErbB receptor, or which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be used in methods of diagnosis or treatment of cancer, and other diseases and disorders.
    Type: Application
    Filed: December 2, 2008
    Publication date: August 13, 2009
    Applicant: Genentech, Inc.
    Inventors: Allen J. Ebens, JR., Frederic S. Jacobson, Paul Polakis, Ralph H. Schwall, Mark X. Sliwkowski, Susan D. Spencer
  • Publication number: 20090155803
    Abstract: This invention relates to methods of analyzing a tissue sample from a subject. In particular the invention combines morphological staining and/or immunohistochemistry (IHC) with fluorescence in situ hybridization (FISH) within the same section of a tissue sample. The analysis can be automated or manual. The invention also relates to kits for use in the above methods.
    Type: Application
    Filed: December 9, 2008
    Publication date: June 18, 2009
    Inventors: Robert L. Cohen, Mary Beth Gardiner, Mark X. Sliwkowski, Gregory T. Stelzer